Human thrombi contain an abundance of active thrombin

Thrombosis and Haemostasis

Volumn 86, Issue 4, 2001, Pages 1028-1034

  Mutch, N J ^a   Robbie, L A ^a   Booth, N A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Active; Re occlusion; Thrombin; Thrombus

Indexed keywords

ANTIBODY; ANTITHROMBIN; FIBRIN; FIBRINOGEN; HIRUDIN; MEIZOTHROMBIN; PEPTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN;

ARTERY; ARTICLE; AUTOPSY; BLOOD VESSEL OCCLUSION; CORRELATION FUNCTION; EXTRACT; HUMAN; HUMAN CELL; HUMAN TISSUE; LYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; THROMBUS; TISSUE SECTION; VEIN; WEIGHT; ZYMOGRAPHY;

EID: 0034759373     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616529     Document Type: Article

References (52)

1. Thrombin as a multifunctional protein: Induction of cell adhesion and proliferation
2. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets
3. Biologic actions of heparin
4. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin
5. Anticoagulantly active heparin-like molecules from vascular tissue
6. Activation of heparin cofactor II by dermatan sulfate
7. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix
8. Interaction of thrombin, antithrombin III and their complex with hepatocytes: Comparison of the molecular components of human and mouse origin
9. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low-density lipoprotein receptor-related proteins 1 and 2
10. LDL receptor-related protein (LRP): A multiligand receptor
11. Note on the adsorption of thrombin on fibrin
12. The binding of thrombin by fibrin
13. Inhibited thrombins: Interaction with fibrinogen and fibrin
14. Fibrin monomer protects from inactivation by heparin-antithrombin III: Implications for heparin efficacy
15. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis
16. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
17. Thrombolytic therapy with tissue-type plasminogen activator or streptokinase induces transient thrombin activity
18. A randomized control trial of intravenous plasminogen activator and early intravenous heparin in acute myocardial infarction
19. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
20. The pathophysiology of the pre-thrombotic state in humans: Insight gained from studies using markers of haemostatic system activation
21. Blood clotting in minimally altered whole blood
22. Thrombin activity of fibrin thrombi and soluble plasmic derivatives
23. Prothrombin-related antigens in human aortic intima
24. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall. A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes
25. α-thrombin within fibrin clots: Inactivation of thrombin by antithrombin-III
26. Proteins of the fibrinolytic system in human thrombi
27. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility
28. The complex between urokinase and its type-1 inhibitor in primary breast cancer: Relation to survival
29. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system
30. 2-macroglobulin receptor
31. Human thrombins: Production, evaluation and properties of α-thrombin
32. A monoclonal antibody enzyme-linked immunosorbent assay (ELISA) directed towards a fibrin binding region of tissue-type plasminogen activator
33. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrinolysis and is cross-linked to fibrin
34. Plasminogen activators in alcoholic cirrhosis: Demonstration of increased tissue-type and urokinase activator
35. Plasminogen activator inhibitor (PAI-1) in plasma and platelets
36. 2-antiplasmin complex as an indicator of in vivo fibrinolysis
37. Protein measurement with the Folin phenol reagent
38. Most clot-bound thrombin activity is inhibited by plasma antithrombin during clot aging, but a very small fraction survives
39. The influence of fibrinogen and fibrin on thrombin generation - Evidence for feedback activation of the clotting system by clot bound thrombin
40. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity
41. Distribution of plasma proteins across the human aortic wall
42. Vitamin K dependent modifications of glutamic acid residues in prothrombin
43. Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and PAI-1 content and distribution
44. The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venom and characterization of the new active intermediates
45. Multiple active forms of thrombin
46. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction
47. Formation of meizothrombin as an intermediate in factor Xa-catalyzed activation
48. Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation on endothelial cells: The influence of thrombin on the reaction mechanism
49. Evidence that meizothrombin is an intermediate product in the clotting of whole blood
50. The roles of protein C and thrombomodulin in the regulation of blood coagulation
51. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor
52. Inhibitors of proteolysis in plasma